Replies to post #140545 on Biotech Values

[oc631]

Maybe I should make this a multiple choice quiz.



Why did BMY withdraw the late-stage, head-to-head study between Peg-lambda and Peg-Alfa?



A- They were unable to enroll patients. Nobody wants to use that shit.

B- The cost of running the late-stage study couldn't be justified since BMY realises the market is going oral.

C- BMY was worried Lambda would show inferior efficacy and/or safety in the head-to-head late-stage trial.

D- All the above.

[iwfal]

Ifn-lambda

Any idea why they canceled this study?




clinicaltrials.gov/ct2/show/NCT01447394

Probably because they will already have the data from the previous large randomized ph ii (interim results here #msg-61755220) - but they want to pursue a different path to approval than as a single agent in a traditional treatment regimen (e.g. perhaps they want to get it approved as part of a BMY regimen).

[ciotera]

Any idea why they [BMY] canceled this [lambda] study?

No idea.. difficulty recruiting for a non-DAA study?
They are however still testing it against alpha with their own DAAs.